文献速递神经肿瘤

阿帕替尼(YN968D1)与替莫唑胺治疗复发性侵袭性垂体腺瘤:病例报告与文献复习

Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review.
PubMed 文献 · World Neurosurg · 2019-01-11

本文报告一例41岁女性生长激素(GH)分泌型侵袭性垂体腺瘤患者,3年内接受4次手术和1次立体定向放射外科治疗,结果不佳。第4次手术后2个月开始口服替莫唑胺(200 mg/m2,第1-5天,28天周期)和阿帕替尼(0.425 g,每日口服),治疗1年后GH水平降至正常,肿瘤体积缩小>90%,随访31.5个月无复发证据。

要点

  • 替莫唑胺联合阿帕替尼治疗复发性侵袭性垂体腺瘤,1年后GH正常、肿瘤缩小>90%。
  • 随访31.5个月,影像学和血清GH均无复发证据。
  • 侵袭性垂体腺瘤血管内皮生长因子表达较高,抗血管生成药物已用于少数侵袭性或恶性垂体瘤复发后。

核心结论

  • 替莫唑胺联合阿帕替尼成功治疗该例复发性侵袭性垂体腺瘤患者31.5个月无复发。
  • 血管生成是常规治疗无法控制的侵袭性垂体腺瘤中的活跃过程。

研究设计与样本

  • 病例报告及文献复习,报告1例41岁女性GH分泌型侵袭性垂体腺瘤患者。

主要发现

  • 患者3年内接受4次手术和1次立体定向放射外科治疗,结果不佳。
  • 第4次手术后2个月开始口服替莫唑胺(200 mg/m2,第1-5天,28天周期)和阿帕替尼(0.425 g,每日口服)。
  • 治疗1年后GH水平降至正常,肿瘤体积缩小>90%。
  • 随访31.5个月,影像学和血清GH均无复发证据。

关键数值与推荐

  • 替莫唑胺剂量为200 mg/m2,第1-5天给药,28天周期,口服。
  • 阿帕替尼剂量为0.425 g,每日口服。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive pituitary adenomas often recurred after postoperative radiotherapy and are difficult to treat. Temozolomide is an alkylating cytostaticum and has been reported to reduce pituitary tumor size and hormone hypersecretion. However, this is far from enough. Pituitary adenomas have relatively high expression of vascular endothelial growth factor. Therefore an antiangiogenic agent has been used in a small number of aggressive or malignant pituitary tumors after recurrence. Apatinib (YN968D1) is a small-molecule antiangiogenic agent that selectively inhibits VEGFR-2 and also mildly inhibits c-Kit and c-Src tyrosine kinases, abundant in invasive pituitary adenomas. CASE DESCRIPTION: We present a 41-year-old female with a growth hormone (GH)-secreting invasive pituitary adenoma causing menstrual disorder and headache symptoms. Over 3 years, she underwent 4 surgeries and a stereotactic radiosurgery, but the results were poor. Two months after the fourth operation, she started treatment with temozolomide (200 mg/m2, days 1-5, 28 days, orally) and apatinib (0.425 g, daily, orally). Her GH level dropped to normal with a >90% decrease in tumor size, after 1-year treatment. There was no evidence of recurrence by imaging or by serum GH levels over 31.5 months of follow-up. CONCLUSIONS: We successfully treated this patient with recurrent invasive pituitary adenoma with temozolomide and apatinib for 31.5 months without recurrence. Angiogenesis is an active process in the cases of invasive pituitary adenomas that cannot be controlled by conventional therapy.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang Y, He Q, Meng X, et al. Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review. World Neurosurg. 2019. PMID: 30639490. doi:10.1016/j.wneu.2018.12.174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。